Klotho Neurosciences, Inc. (NASDAQ:KLTO) Sees Significant Increase in Short Interest

Klotho Neurosciences, Inc. (NASDAQ:KLTO) was the target of a large increase in short interest in February. As of February 27th, there was short interest totaling 2,203,718 shares, an increase of 212.0% from the February 12th total of 706,392 shares. Based on an average trading volume of 6,530,944 shares, the short-interest ratio is currently 0.3 days. Approximately 3.3% of the company’s stock are sold short. Approximately 3.3% of the company’s stock are sold short. Based on an average trading volume of 6,530,944 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on KLTO. Weiss Ratings reiterated a “sell (e+)” rating on shares of Klotho Neurosciences in a report on Monday, December 29th. Wall Street Zen upgraded shares of Klotho Neurosciences to a “hold” rating in a report on Saturday, February 28th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Klotho Neurosciences presently has a consensus rating of “Sell”.

Klotho Neurosciences Price Performance

Shares of Klotho Neurosciences stock remained flat at $0.52 on Friday. The firm has a 50-day moving average of $0.34 and a 200 day moving average of $0.45. Klotho Neurosciences has a one year low of $0.11 and a one year high of $3.91. The company has a market capitalization of $38.55 million, a P/E ratio of -1.64 and a beta of 9.08.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in Klotho Neurosciences by 51.8% in the 4th quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after acquiring an additional 167,905 shares during the period. Renaissance Technologies LLC bought a new position in Klotho Neurosciences during the fourth quarter worth about $126,000. Jane Street Group LLC bought a new position in Klotho Neurosciences during the fourth quarter worth about $64,000. XTX Topco Ltd increased its stake in shares of Klotho Neurosciences by 101.2% in the fourth quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock worth $46,000 after purchasing an additional 80,768 shares in the last quarter. Finally, Brummer Multi Strategy AB bought a new stake in shares of Klotho Neurosciences in the fourth quarter valued at approximately $175,000. Institutional investors own 20.07% of the company’s stock.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.